Beryl Drugs manufactures pharmaceutical products, specifically small-volume injectables and fluids using Blow-Fill-Seal technology, primarily serving government medical corporations and institutional clients in India.
The company lacks a durable moat, evidenced by an average ROCE of 6.7% which likely sits below its cost of capital. While they hold a WHO-GMP certification, this is a regulatory baseline rather than a competitive edge, as seen in the volatile margins and inability to maintain revenue growth.
Management has prioritized reinvestment into plant upgrades to meet regulatory standards (Schedule M/WHO-GMP) rather than shareholder returns. However, these investments have resulted in a negative EPS CAGR of -8.2%, suggesting poor incremental returns on retained capital.
The company's demise was driven by a toxic combination of regulatory obsolescence and capital destruction. Despite repeated investments in plant upgrades, the firm failed to maintain compliance, leading to a permanent manufacturing shutdown by the FDA. The capital allocated to these upgrades yielded negative returns, while the concentration of receivables with government entities resulted in massive write-offs that evaporated the remaining liquidity. By the time the debt service coverage ratio hit a breaking point, the lack of transparency regarding internal audits and related-party dealings with Aminova Infusions had already alienated the last of the institutional trust, leaving the business a hollow shell of stranded assets.
RichFakir rates Beryl Drugs Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Beryl Drugs Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Beryl Drugs Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Beryl Drugs Ltd's fair value is about ₹6 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →